<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background/Aims: Transcriptional repression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes is determined by the quantity of promoter hypermethylation </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed the methylation quantity of CDKN2B in pediatric <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Methods: Quantitative measurement of CDKN2B methylation was performed in 25 pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and 12 controls using pyrosequencing, and the result was compared with those from 74 adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases and 31 adult controls </plain></SENT>
<SENT sid="3" pm="."><plain>The association between CDKN2B methylation quantity and factors related to prognosis including bone marrow blast percentage and karyotype was analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>Results: Pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients showed a higher methylation level (MtL) of CDKN2B than pediatric controls (2.94 vs. 1.62; p = 0.031) but a lower level than adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (8.76; p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>MtL was higher in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases with &gt;5% blasts than in pediatric controls (3.78 vs. 1.62; p = 0.052) </plain></SENT>
<SENT sid="6" pm="."><plain>Pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases with abnormal karyotype showed a higher MtL than pediatric controls (5.95 vs. 1.62; p = 0.045) </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusions: We confirmed that methylation of CDKN2B is associated with the pathogenesis and prognosis in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The difference in MtLs between pediatric and adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> might be related to the physiological hypermethylation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes in aging </plain></SENT>
</text></document>